Table 5.
Standard treatment before LCIG or CSAI implementation and in patients continuing with SOC
| Parameter | N (%) | No. of tablets/day (mean ± SD) (range) | LEDD (mg) (mean ± SD) (range) |
|---|---|---|---|
| Standard treatments before LCIG (N = 50) | |||
| Oral levodopa | 50 (94%) | 6.0 ± 1.4 (2–9) | 972.5 ± 417.9 (250–2350) |
| Dopamine agonists | 33 (62%) | 1.5 ± 0.7 (1–3) | 274.6 ± 123.9 (100–560) |
| COMT inhibitors | 23 (43%) | 4.3 ± 1.9 (1–10) | 322.6 ± 230.8 (100–1200) |
| MAO inhibitors | 17 (32%) | 1.1 ± 0.2 (1–2) | 100.0 ± 0.0 (100–100) |
| Othersa | 12 (23%) | 2.6 ± 2.4 (1–10) | 204.3 ± 108.3 (100–360) |
| Standard treatments before CSAI (N = 19) | |||
| Oral levodopa | 19 (100%) | 6.3 ± 1.8 (4–10) | 1185 ± 686.3 (500–2500) |
| Dopamine agonists | 12 (63%) | 2.4 ± 2 (2–8) | 437.2 ± 596.5 (105–2000) |
| COMT inhibitors | 13 (68%) | 4.4 ± 1.8 (2–8) | 442.7 ± 403.1 (75–1400) |
| MAO inhibitors | 3 (16%) | 1 ± 0 (1–1) | 100 ± 0 (100–100) |
| Amantadine | 1 (5%) | 2 | 200 (200–200) |
| Standard treatments in SOC-continuing patients (N = 54) | |||
| Oral levodopa | 54 (100%) | 5.6 ± 1.8 (2–12) | 732.6 ± 230.1 (200–1200) |
| Dopamine agonists | 36 (67%) | 1.4 ± 1.2 (1–8) | 211.6 ± 81.0 (100–360) |
| COMT inhibitors | 20 (37%) | 4.5 ± 1.4 (2–7) | 548.7 ± 414.0 (132–1400) |
| MAO inhibitors | 19 (35%) | 1.3 ± 1.2 (1–6) | 237.5 ± 388.9 (100–1200) |
| Othersb | 15 (28%) | 2.3 ± 1.3 (1–5) | 293.2 ± 443.9 (100–1625) |
SD standard deviation
aOthers in LCIG group = amantadine (n = 9), apomorphine pen (n = 1), rasagiline (n = 1), rotigotine (n = 1)
bOthers in the SOC group = amantadine (n = 11), levodopa/carbidopa/entacapone (n = 1), trihexyphenidyl hydrochloride (n = 1), clonazepam (n = 1)